Skip to main content

Market Overview

Why Is Neurocrine Biosciences Stock Trading Lower Today?

Share:
Why Is Neurocrine Biosciences Stock Trading Lower Today?

Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIXreleased Phase 2 study results from two signal-seeking pipeline programs in focal onset seizures and anhedonia.

The investigational selective NaV 1.6 inhibitor, NBI-921352, licensed from Xenon Pharmaceuticals Inc (NASDAQ: XENE), failed to demonstrate meaningful seizure frequency reduction in the Phase 2 dose-finding study as adjunctive therapy in adults with focal onset seizures. 

No further development with NBI-921352 in Focal Onset Seizure (FOS) is currently planned. 

Neurocrine is reviewing the data from the FOS study to understand any potential implication for its ongoing study in SCN8A-developmental epileptic encephalopathy and will provide an update once this review is complete. 

The investigational NBI-1065846, as part of the collaboration with Takeda Pharmaceutical Company Limited (NYSE: TAK), did not meet its primary endpoint in the Phase 2 TERPSIS study evaluating its efficacy compared to placebo in patients with anhedonia in major depressive disorder. 

No further development with NBI-1065846 is planned at this time. 

Neurocrine and Takeda continue to collaborate on several programs in clinical development, including NBI-1065845 for inadequate response to treatment in major depressive disorder (Phase 2), luvadaxistat for cognitive impairment associated with schizophrenia (Phase 2), and NBI-1070770 for major depressive disorder (Phase 1).

Mizuho lowered the price target from $116 to $144 and maintains the Neutral rating.

The analyst removed risk-adjusted revenues for NBI-921352 in FOS and NBI-1065846 in Anhedonia.

The analyst says the targeted sodium channel inhibition with NBI-921352 could have a better chance of showing a clear signal in SCN8A-DEE when the trial reads out in 2024, as SCN8A-DEE is caused by a gain-of-function mutation of the NaV1.6 sodium channel, which is NBI-92135's target. 

Price Action: NBIX shares are down 5.50% at $105.98 on the last check Friday.

Latest Ratings for NBIX

DateFirmActionFromTo
Mar 2022Piper SandlerDowngradesOverweightNeutral
Feb 2022Goldman SachsUpgradesNeutralBuy
Feb 2022Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for NBIX

View the Latest Analyst Ratings

 

Related Articles (NBIX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Price Target Small Cap Analyst Ratings Movers

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com